Also known as: NIPT · Non-invasive prenatal screening · Cell-free fetal DNA test · cfDNA screening
Safe, early screening for common chromosomal conditions from a simple maternal blood draw — from 10 weeks of pregnancy, with no risk to the baby.
This page and the corresponding laboratory report are overseen by an in-house clinician to ensure medical accuracy and patient safety.
“NIPT offers expectant parents meaningful, early insight without any procedure-related risk to the pregnancy. It is a screening test — any high-risk result is confirmed with a diagnostic procedure before clinical decisions are made.”
Dr. Ibrahim Musa, MBBS, FMCPaed, Cert. Medical Genetics
Consider NIPT if you:
NIPT is a screening test. A high-risk result requires confirmatory diagnostic testing before any clinical decision.
No fasting is required.
Gestational age must be at least 10 weeks for reliable results. Please bring your most recent ultrasound scan report or an accurate estimate of gestational age.
Please inform us of any recent transfusion, transplant or malignancy, as these can affect the analysis.
Cell-free fetal DNA circulating in maternal plasma is sequenced by next-generation sequencing (NGS) and analysed for relative chromosome dosage. Bioinformatic pipelines calculate a risk score for trisomies 21, 18 and 13, with optional sex chromosome aneuploidy reporting where requested.
Fetal fraction is assessed to confirm result reliability.
Next-generation sequencing (NGS) platforms with validated non-invasive prenatal screening bioinformatics pipelines and fetal fraction quantification.
Your results are delivered securely as an encrypted, password-protected PDF to your registered email address and WhatsApp. The file is never sent unprotected. Results are issued as an encrypted, password-protected PDF to registered email and WhatsApp. Pre- and post-test genetic counseling is available and recommended for all results.
Certified genetic counselors are available before and after your test to explain what the results mean, discuss implications for your family, and guide any next clinical steps.
Yes. NIPT requires only a maternal blood draw. There is no procedure-related risk of miscarriage or harm to the pregnancy.
From 10 weeks of gestation. Earlier testing can yield insufficient fetal fraction and require a redraw.
No. NIPT is a screening test with a high detection rate but is not diagnostic. A high-risk result should be confirmed with a diagnostic procedure such as amniocentesis.
Fetal fraction is the proportion of cell-free DNA in maternal blood that originates from the placenta. A sufficient fraction is required for a reliable result; if too low, a redraw is offered.
Fetal sex reporting is technically available where requested and permitted. Discuss your preferences with a genetic counselor before testing.
Maternal blood collection is available at our Abuja, Lagos and Kaduna centres by certified phlebotomists.